Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients

Clinical Biochemistry

Volumn 42, Issue 12, 2009, Pages 1252-1259

  Peng, Wen Hui ^a   Lu, Lin ^a   Hu, Jian ^a   Yan, Xiao Xiang ^a   Zhang, Qi ^a   Zhang, Rui Yan ^a   Chen, Qiu Jin ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

C reactive protein; Diabetes mellitus; Endogenous secretory receptor for advanced glycation endproducts; Plaque progression

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA GLUCOSIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

AGED; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS;

EID: 67650729689     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.04.017     Document Type: Article

References (37)

1. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
2. Boyle P.J. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120 (2007) S12-S17
3. Kosuge M., Kimura K., Kojima S., et al. Effects of glucose abnormalities on in-hospital outcome after coronary intervention for acute myocardial infarction. Circ. J. 69 (2005) 375-379
4. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
5. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
6. Neeper M., Schmidt A.M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992) 14998-15004
7. Yamamoto Y., Yamagishi S., Yonekura H., et al. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann. N.Y. Acad. Sci. 902 (2000) 163-170
8. Bucciarelli L.G., Wendt T., Qu W., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
9. Forbes J.M., Yee L.T., Thallas V., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53 (2004) 1813-1823
10. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196 (2008) 9-21
11. Raucci A., Cugusi S., Antonelli A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22 (2008) 3716-3727
12. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1109
13. Yan XX, Lu L, Peng WH, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2008 Dec 14. [Epub ahead of print]
14. Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2008 Sep 2. [Epub ahead of print].
15. Katakami N., Matsuhisa M., Kaneto H., and Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 190 (2007) 22-23
16. Katakami N., Matsuhisa M., Kaneto H., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
17. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb. Vasc. Biol. 25 (2005) 2587-2593
18. Sakurai S., Yamamoto Y., Tamei H., et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res. Clin. Pract. 73 (2006) 158-165
19. Lu L., Jin Pu L., Chen Q.J., et al. Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients. Clin. Chim. Acta 396 (2008) 33-37
20. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352 (2005) 29-38
21. Anand D.V., Lim E., Darko D., et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J. Am. Coll. Cardiol. 50 (2007) 2218-2225
22. Lu L., Pu L.J., Xu X.W., et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin. Biochem. 40 (2007) 810-816
23. Waters D., Lesperance J., Craven T.E., Hudon G., and Gillam L.D. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials. Circulation 87 (1993) II38-II47
24. Berry C., L'Allier P.L., Gregoire J., et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation 115 (2007) 1851-1857
25. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
26. Park I.H., Yeon S.I., Youn J.H., et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol. Immunol. 40 (2004) 1203-1211
27. Harashima A., Yamamoto Y., Cheng C., et al. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem. J. 396 (2006) 109-115
28. Elias-Smale S.E., Kardys I., Oudkerk M., Hofman A., and Witteman J.C. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. Atherosclerosis 195 (2007) e195-e202
29. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
30. Jang Y., Kim J.Y., Kang S.M., et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56 (2007) 199-205
31. Radaelli A., Loardi C., Cazzaniga M., et al. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb. Vasc. Biol. 27 (2007) 2750-2755
32. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108 (2001) 949-955
33. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1067-1075
34. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., and Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316 (1987) 1371-1375
35. Schoenhagen P., Ziada K.M., Kapadia S.R., Crowe T.D., Nissen S.E., and Tuzcu E.M. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101 (2000) 598-603
36. Nicholls S.J., Tuzcu E.M., Kalidindi S., et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J. Am. Coll. Cardiol. 52 (2008) 255-262
37. Jimenez-Quevedo P., Suzuki N., Corros C., et al. Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. Diabetes 58 (2009) 209-214